Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Feb 1;97(3):839–844. doi: 10.1172/JCI118484

Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.

M Azizi 1, A Rousseau 1, E Ezan 1, T T Guyene 1, S Michelet 1, J M Grognet 1, M Lenfant 1, P Corvol 1, J Ménard 1
PMCID: PMC507123  PMID: 8609242

Abstract

Angiotensin I-converting enzyme (ACE) has two homologous active NH2- and COOH-terminal domains and displays activity toward a broad range of substrates. The tetrapeptide N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) has been shown to be hydrolyzed in vitro by ACE and to be a preferential substrate for its NH2-terminal active site. This peptide is a regulatory factor of hematopoiesis which reversibly stem cells and normal early progenitors into S-phase. We found that a single oral dose of 50 mg of the ACE inhibitor, captopril, when administered to eight healthy subjects in a double-blind, crossover, placebo-controlled study, massively increased the plasma level of Ac-SDKP. ACE inhibition by captopril induced a 90-99% inhibition of in vitro [3H]Ac-SDKP hydrolysis and a long-lasting 5.5-fold (range: 4-8.5-fold) increase in the plasma levels of Ac-SDKP. These results demonstrate that Ac-SDKP is the first natural peptide hydrolyzed by the NH2-terminal domain of ACE not only in vitro but also in vivo, confirming that both catalytic sites of ACE are physiologically active. Our data suggest that ACE may also be implicated in the process of hematopoietic stem cell regulation, by permanently degrading this natural circulating inhibitor of cell entry into S-phase.

Full Text

The Full Text of this article is available as a PDF (159.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bogden A. E., Carde P., de Paillette E. D., Moreau J. P., Tubiana M., Frindel E. Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation. Ann N Y Acad Sci. 1991;628:126–139. doi: 10.1111/j.1749-6632.1991.tb17230.x. [DOI] [PubMed] [Google Scholar]
  2. Bonnet D., Lemoine F. M., Pontvert-Delucq S., Baillou C., Najman A., Guigon M. Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors. Blood. 1993 Dec 1;82(11):3307–3314. [PubMed] [Google Scholar]
  3. Bygrave F. L., Benedetti A. Calcium: its modulation in liver by cross-talk between the actions of glucagon and calcium-mobilizing agonists. Biochem J. 1993 Nov 15;296(Pt 1):1–14. doi: 10.1042/bj2960001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carde P., Chastang C., Goncalves E., Mathieu-Tubiana N., Vuillemin E., Delwail V., Corbion O., Vekhoff A., Isnard F., Ferrero J. M. Séraspénide (acétylSDKP): étude en phase I-II d'un inhibiteur de l'hématopoïse la protégeant de la toxicité de monochimiothérapies aracytine et ifosfamide. C R Acad Sci III. 1992;315(13):545–550. [PubMed] [Google Scholar]
  5. Erdös E. G. Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture. Hypertension. 1990 Oct;16(4):363–370. doi: 10.1161/01.hyp.16.4.363. [DOI] [PubMed] [Google Scholar]
  6. Ezan E., Carde P., Le Kerneau J., Ardouin T., Thomas F., Isnard F., Deschamps de Paillette E., Grognet J. M. Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis. Drug Metab Dispos. 1994 Nov-Dec;22(6):843–848. [PubMed] [Google Scholar]
  7. Grillon C., Rieger K., Bakala J., Schott D., Morgat J. L., Hannappel E., Voelter W., Lenfant M. Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system. FEBS Lett. 1990 Nov 12;274(1-2):30–34. doi: 10.1016/0014-5793(90)81322-f. [DOI] [PubMed] [Google Scholar]
  8. Hirakata H., Onoyama K., Iseki K., Kumagai H., Fujimi S., Omae T. Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol. 1984;4(6):355–360. doi: 10.1159/000166851. [DOI] [PubMed] [Google Scholar]
  9. Imbs J. L., Bakish D., Schmidt M., Schwartz J. Low temperature sustains inhibition of angiotensin-converting-enzyme activity in serum from patients taking captopril. N Engl J Med. 1981 Jul 23;305(4):229–229. doi: 10.1056/NEJM198107233050425. [DOI] [PubMed] [Google Scholar]
  10. Jaspard E., Wei L., Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem. 1993 May 5;268(13):9496–9503. [PubMed] [Google Scholar]
  11. Juillerat L., Nussberger J., Ménard J., Mooser V., Christen Y., Waeber B., Graf P., Brunner H. R. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990 Nov;16(5):564–572. doi: 10.1161/01.hyp.16.5.564. [DOI] [PubMed] [Google Scholar]
  12. Lenfant M., Wdzieczak-Bakala J., Guittet E., Prome J. C., Sotty D., Frindel E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci U S A. 1989 Feb;86(3):779–782. doi: 10.1073/pnas.86.3.779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lombard M. N., Sotty D., Wdzieczak-Bakala J., Lenfant M. In vivo effect of the tetrapeptide, N-acetyl-Ser-Asp-Lys-Pro, on the G1-S transition of rat hepatocytes. Cell Tissue Kinet. 1990 Mar;23(2):99–103. doi: 10.1111/j.1365-2184.1990.tb01336.x. [DOI] [PubMed] [Google Scholar]
  14. McAreavey D., Brown W. B., Murray G. D., Robertson J. I. Exchangeable sodium in DOC-salt and post-DOC-salt hypertension in rats. J Hypertens. 1985 Jun;3(3):275–279. doi: 10.1097/00004872-198506000-00013. [DOI] [PubMed] [Google Scholar]
  15. Nguyen L., Ward W. F., Ts'ao C. H., Molteni A. Captopril inhibits proliferation of human lung fibroblasts in culture: a potential antifibrotic mechanism. Proc Soc Exp Biol Med. 1994 Jan;205(1):80–84. doi: 10.3181/00379727-205-43681. [DOI] [PubMed] [Google Scholar]
  16. Nussberger J., Brunner D. B., Waeber B., Brunner H. R. In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II. Life Sci. 1988;42(17):1683–1688. doi: 10.1016/0024-3205(88)90448-1. [DOI] [PubMed] [Google Scholar]
  17. Powell J. S., Clozel J. P., Müller R. K., Kuhn H., Hefti F., Hosang M., Baumgartner H. R. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989 Jul 14;245(4914):186–188. doi: 10.1126/science.2526370. [DOI] [PubMed] [Google Scholar]
  18. Pradelles P., Frobert Y., Créminon C., Ivonine H., Frindel E. Distribution of a negative regulator of haematopoietic stem cell proliferation (AcSDKP) and thymosin beta 4 in mouse tissues. FEBS Lett. 1991 Sep 9;289(2):171–175. doi: 10.1016/0014-5793(91)81062-d. [DOI] [PubMed] [Google Scholar]
  19. Pradelles P., Frobert Y., Créminon C., Liozon E., Massé A., Frindel E. Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Biochem Biophys Res Commun. 1990 Aug 16;170(3):986–993. doi: 10.1016/0006-291x(90)90489-a. [DOI] [PubMed] [Google Scholar]
  20. Rigat B., Hubert C., Corvol P., Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res. 1992 Mar 25;20(6):1433–1433. doi: 10.1093/nar/20.6.1433-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Robinson S., Lenfant M., Wdzieczak-Bakala J., Melville J., Riches A. The mechanism of action of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in the control of haematopoietic stem cell proliferation. Cell Prolif. 1992 Nov;25(6):623–632. doi: 10.1111/j.1365-2184.1992.tb01464.x. [DOI] [PubMed] [Google Scholar]
  22. Rousseau A., Michaud A., Chauvet M. T., Lenfant M., Corvol P. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem. 1995 Feb 24;270(8):3656–3661. doi: 10.1074/jbc.270.8.3656. [DOI] [PubMed] [Google Scholar]
  23. Shand B. I., Gilchrist N. L., Nicholls M. G., Bailey R. R. Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study. J Hum Hypertens. 1995 Apr;9(4):233–235. [PubMed] [Google Scholar]
  24. Skidgel R. A., Erdös E. G. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens A. 1987;9(2-3):243–259. doi: 10.3109/10641968709164184. [DOI] [PubMed] [Google Scholar]
  25. Vlahakos D. V., Canzanello V. J., Madaio M. P., Madias N. E. Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis. 1991 Feb;17(2):199–205. doi: 10.1016/s0272-6386(12)81129-2. [DOI] [PubMed] [Google Scholar]
  26. Ward W. F., Molteni A., Ts'ao C. H., Hinz J. M. Captopril reduces collagen and mast cell accumulation in irradiated rat lung. Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1405–1409. doi: 10.1016/0360-3016(90)90351-j. [DOI] [PubMed] [Google Scholar]
  27. Wdzieczak-Bakala J., Fache M. P., Lenfant M., Frindel E., Sainteny F. AcSDKP, an inhibitor of CFU-S proliferation, is synthesized in mice under steady-state conditions and secreted by bone marrow in long-term culture. Leukemia. 1990 Mar;4(3):235–237. [PubMed] [Google Scholar]
  28. Wei L., Alhenc-Gelas F., Corvol P., Clauser E. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem. 1991 May 15;266(14):9002–9008. [PubMed] [Google Scholar]
  29. Wei L., Clauser E., Alhenc-Gelas F., Corvol P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem. 1992 Jul 5;267(19):13398–13405. [PubMed] [Google Scholar]
  30. Yoon S. C., Park J. M., Jang H. S., Shinn K. S., Bahk Y. W. Radioprotective effect of captopril on the mouse jejunal mucosa. Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):873–878. doi: 10.1016/0360-3016(94)90363-8. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES